Clinical Trial Results:
Phase II, multicenter, randomized, parallel-group, partially blinded, placebo and Avonex controlled dose finding study to evaluate the efficacy, as measured by brain MRI lesions, and safety of 2 dose regimens of ocrelizumab in patients with relapsing-remitting multiple sclerosis
Summary
|
|
EudraCT number |
2007-006338-32 |
Trial protocol |
FR GB DE ES CZ SK DK BE NL FI BG IT |
Global completion date |
09 Mar 2012
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
No
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
No
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
No
|
Results information
|
|
Results version number |
v1 |
This version publication date |
08 Jul 2016
|
First version publication date |
22 Mar 2015
|
Other versions |
v2 |
Summary report(s) |
WA21493 (CSR synopsis) |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.